Login / Signup

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.

Jennifer R DiamondS G EckhardtTodd M PittsAdrie van BokhovenDara AisnerDaniel L GustafsonAnna CapassoSharon SamsPeter KabosKathryn ZolmanTiffany ColvinAnthony D EliasAnna M StornioloBryan P SchneiderDexiang GaoJohn J TentlerVirginia F BorgesKathy D Miller
Published in: Breast cancer research : BCR (2018)
ClinicalTrials.gov, NCT01639248 . Registered on July 12, 2012.
Keyphrases
  • phase ii
  • clinical trial
  • open label
  • squamous cell carcinoma
  • small cell lung cancer
  • double blind
  • phase iii